Gilead Sciences Spikes Amid CVS Formulary Status

Loading...
Loading...

Shares of Gilead Sciences, Inc. GILD spiked up over 3 percent Monday amid news that CVS Health Corp CVS gave preferred formulary status to the company’s Harvoni and Sovaldi drugs.

The news followed a positive report from Morgan Stanley on Gilead’s market share.

Gilead Sciences recently traded at $96.33, up 1.5 percent.

Posted In: NewsHealth CareGeneralMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...